FDA
-
-
-
-
-
-
-
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
FDA agrees to review Cogent's bezuclastinib application for rare cancer
-
-
-
-
-
-
-
Cogent (COGT) PT Raised to $52 at H.C. Wainwright
-
-
-
-
-
-
-
Cogent (COGT) PT Raised to $50 at Leerink Partners
-
-
-
-
-
-
-
Cogent Biosciences receives FDA breakthrough therapy designation
-
-
-
-
-
-
-
Cogent Biosciences (COGT) Reports Positive FDA Meeting and Alignment on MS2D2
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

